53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-002470-32-NL
(EUCTR)
12/12/202223/07/2021NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patientsNEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients - NECESSITY Primary Sjögren’s syndrome (pSS)
MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Trade Name: PLAQUENIL
Product Name: Hydroxychloroquine
INN or Proposed INN: Hydroxychloroquine
Other descriptive name: HYDROXYCHLOROQUINE SULFATE
Trade Name: Mycophenolate mofetil TEVA
Product Name: mycophenolate mofetil
INN or Proposed INN: Mycophenolate mofetil
Other descriptive name: MYCOPHENOLATE MOFETIL
Trade Name: Arava
Product Name: Leflunomide
INN or Proposed INN: LEFLUNOMIDE
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 2Netherlands;Italy
2ChiCTR2200057578
2022-03-012022-03-15Tofacitinib treatment in patients with primary Sjogren syndrome: a prospective pilot trialTofacitinib treatment in patients with primary Sjogren syndrome: a prospective pilot trial Sjogren SyndromeControl group:Same dose of hydroxychloroquine sulfate as before;Intervention group:Tofacitinib 5mg bid po+the same dose of hydroxychloroquine sulfate as before;Ningbo Medical Center Lihuili HospitalNULLPending1570BothControl group:60;Intervention group:60;Phase 4China
3EUCTR2019-002470-32-NO
(EUCTR)
14/12/202126/08/2021NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patientsNEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients - NECESSITY Primary Sjögren’s syndrome (pSS)
MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Trade Name: PLAQUENIL
Product Name: Hydroxychloroquine
INN or Proposed INN: Hydroxychloroquine
Other descriptive name: HYDROXYCHLOROQUINE SULFATE
Trade Name: Mycophenolate mofetil TEVA
Product Name: mycophenolate mofetil
INN or Proposed INN: Mycophenolate mofetil
Other descriptive name: MYCOPHENOLATE MOFETIL
Trade Name: Arava
Product Name: Leflunomide
INN or Proposed INN: LEFLUNOMIDE
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 2Netherlands;Norway;Italy
4EUCTR2019-002470-32-IT
(EUCTR)
05/10/202127/01/2022Nuovi end-points clinici in pazienti con sindrome di Sjögren primaria (pSS): uno studio interventistico basato sulla stratificazione dei pazienti.NEw Clinical End-points in patients with primary Sjögren's Syndrome (pSS): an Interventional Trial based on stratifYing patients - NECESSITY Primary Sjögren's syndrome (pSS)
MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Trade Name: Arava
Product Name: Leflunomide
Product Code: [Leflunomide]
INN or Proposed INN: LEFLUNOMIDE
Trade Name: Mycophenolate mofetil TEVA
Product Name: mycophenolate mofetil
Product Code: [mycophenolate mofetil]
INN or Proposed INN: MICOFENOLATO MOFETILE
Trade Name: PLAQUENIL
Product Name: Hydroxychloroquine
Product Code: [Hydroxychloroquine]
INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE
ASSITANCE PUBLIQUE DES HOPITAUX DE PARISNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 2France;Greece;Spain;Norway;Netherlands;United Kingdom;Italy;Sweden
5ITMCTR2000003900
2020-09-082020-09-08Bushen Qingre Runzao decoction for primary Sjogren's syndrome: a randomized controlled trialBushen Qingre Runzao decoction for primary Sjogren's syndrome: a randomized controlled trial Primary Sjogren's syndromeControl group:Hydroxychloroquine sulfate tablets 200ml bid po;Experimental group:Bushen Qingre Runzao Decoction 200ml bid po;China-Japan Friendship HospitalNULLRecruiting1875BothControl group:48;Experimental group:48;N/AChina
6ChiCTR2000037989
2020-09-082020-09-08Bushen Qingre Runzao decoction for primary Sjogren's syndrome: a randomized controlled trial Bushen Qingre Runzao decoction for primary Sjogren's syndrome: a randomized controlled trial Primary Sjogren's syndromeExperimental group:Bushen Qingre Runzao Decoction 200ml bid po;Control group:Hydroxychloroquine sulfate tablets 200ml bid po;China-Japan Friendship HospitalNULLRecruiting1875BothExperimental group:48;Control group:48;N/AChina
7EUCTR2007-005218-38-FR
(EUCTR)
31/01/200820/11/2007Essai prospectif Randomisé contre placebo en double aveugle de l’hydroxychloroQUine dans le traitement du syndrome de sJOgren primitif (JOQUER) - JOQUEREssai prospectif Randomisé contre placebo en double aveugle de l’hydroxychloroQUine dans le traitement du syndrome de sJOgren primitif (JOQUER) - JOQUER Syndrome de Sjögren primitif
MedDRA version: 8.1;Level: PT;Classification code 10042846;Term: Syndrome Sjogren's
Trade Name: Plaquenil
Product Name: Plaquenil
INN or Proposed INN: Sulfate d'hydroxychloroquine
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France